please select
AMS BioteQ Enters Shanghai, Targets China's Health and Wellness Market(圖)
The National Pharmaceutical Trade Fair (PHARMCHINA) was grandly held in Shanghai, China, from May 15 to 17, 2024. It is a large-scale professional exhibition for health nutrition and wellness products in China.
AMS BioteQ Invited to Inaugural CPHI Japan 2024(圖)
CPHI Japan was held grandly from April 17 to 19 this year (2024).
Kaohsiung Medical University and AMS BioteQ signed an MOU for talent cultivation, aiming to foster pharmaceutical research talents and promote industry-academia collaboration.(圖)
In pursuit of academic exchange, fostering industry-academia collaboration, and talent cultivation, the School of Pharmacy at Kaohsiung Medical University and AMS BioteQ recently signed a memorandum of understanding (MOU) to enhance industry-academia exchange, promote the development of the domestic biopharmaceutical industry, and lay the foundation for pharmaceutical research talent cultivation.
AMS BioteQ's International Expansion Facilitates Immediate Aid for Post-War Reconstruction in Ukraine.(圖)
The "Connecting with Ukraine" economic revitalization event, orchestrated by the Japan International Cooperation Agency (JICA), convened from February 15th to 17th, 2024. This gathering served as a platform uniting businesses, manufacturers, and research institutions from Japan and Ukraine, pooling their resources to aid in the post-war reconstruction endeavors of Ukraine.
AMS BioteQ Unveils Breakthrough in Dressing Innovation, Redefining Medical Materials(圖)
On January 18th, AMS BioteQ (TPE: 6864) announced the successful approval of its application for a novel invention patent in Taiwan titled “ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND” by the Intellectual Property Office of the Ministry of Economic Affairs, R.O.C.
AMS BioteQ has achieved significant progress in the global wound dressing market by successfully obtaining U.S. FDA approval.(圖)
AMS BioteQ (TPE: 6864) announced on 11th Dec. last year that its innovative medical care product, "SIPSIP Foam," the wound dressing made of its patented bioengineering technology ExtrO, has successfully obtained the registration number issued by the U.S. FDA.
AMS BioteQ Wound Dressing Approved, Expanding into Innovative Medical Care Market(圖)
AMS BioteQ (stock code: 6864), a leading biotechnology company, announced on the 21st that its innovative medical care material, "SIPSIP Foam Yuanzhang Cotton Wound Dressing," has successfully obtained approval from the Taiwan Food and Drug Administration (TFDA), with a medical device approval permit number.
Outbreak of Dengue Fever: AMS BioteQ Develops Small Molecule Drugs(圖)
In southern Taiwan, there is a significant outbreak of Dengue fever, with the number of infections surpassing thousands of cases this year, reaching a new high for the same period in the past ten years according to statistics from the Centers for Disease Control (CDC). In order to overcome the challenges in treating De
#GO 2023 Medical Japan Tokyo Exclusive Interview(圖)
GeneOnline had an exclusive interview with Taiwan’s 元樟生技 AMS BioteQ at the #2023_Medical_Japan_Tokyo.
AMS BioteQ Debuts in Medical Japan Tokyo 2023: Expanding into New Healthcare Markets(圖)
Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the spotlight.
Breaking Boundaries in Wound Care, AMS BioteQ at Medical Japan 2023(圖)
AMS BioteQ: Pioneering Innovation in Antibiotics and Advanced Dressings
Since its establishment in 2018, AMS BioteQ, headquartered in Taiwan, has dedicated itself to the development of cutting-edge antibiotics and antimicrobial dressings.
Breaking Through the Dengue Fever Treatment(圖)
Despite the ongoing prevalence of dengue fever in Taiwan, the primary method of epidemic prevention in our country still relies on traditional mosquito spray.